Eptinézumab (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Eptinézumab" in French language version.

refsWebsite

Global rank French rank

4^th place

12^th place

2^nd place

3^rd place

11^th place

325^th place

731^st place

771^st place

9,919^th place

3,656^th place

2,650^th place

689^th place

low place

doi.org

(en) D.W. Dodick, P.J. Goadsby, S.D. Silberstein, R.B. Lipton, J. Olesen, M. Ashina, K. Wilks, D. Kudrow, R. Kroll, B. Kohrman, R. Bargar, J. Hirman, J. Smith, « Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial », The Lancet. Neurology, vol. 13, n^o 11,‎ 2014, p. 1100–1107 (PMID 25297013, DOI 10.1016/S1474-4422(14)70209-1, S2CID 206161999)

(en) Matt Hoffman, « Eptinezumab Approved for Migraine Prevention », sur www.neurologylive.com, NeurologyLive, 25 février 2020 (consulté le 9 novembre 2020).

(en) D.W. Dodick, P.J. Goadsby, S.D. Silberstein, R.B. Lipton, J. Olesen, M. Ashina, K. Wilks, D. Kudrow, R. Kroll, B. Kohrman, R. Bargar, J. Hirman, J. Smith, « Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial », The Lancet. Neurology, vol. 13, n^o 11,‎ 2014, p. 1100–1107 (PMID 25297013, DOI 10.1016/S1474-4422(14)70209-1, S2CID 206161999)

(en) D.W. Dodick, P.J. Goadsby, S.D. Silberstein, R.B. Lipton, J. Olesen, M. Ashina, K. Wilks, D. Kudrow, R. Kroll, B. Kohrman, R. Bargar, J. Hirman, J. Smith, « Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial », The Lancet. Neurology, vol. 13, n^o 11,‎ 2014, p. 1100–1107 (PMID 25297013, DOI 10.1016/S1474-4422(14)70209-1, S2CID 206161999)